About Insmed
Insmed is a company based in Bridgewater (United States) founded in 1999. The company has 1,270 employees. Insmed has completed 2 acquisitions, including Adrestia and Transave. Insmed offers products and services including ARIKAYCE, Brensocatib, and TPIP. Insmed operates in a competitive market with competitors including Affinivax, Eligo Bioscience, Aridis Pharma, Basilea and MaaT Pharma, among others.
- Headquarter Bridgewater, United States
- Employees 1,270
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website insmed.com
- Social LinkedIn X YouTube
- Legal Name Insmed Incorporated
- Annual Revenue$606.42 M (USD)66.73as on Dec 31, 2025
- Net Profit-$1.28 B (USD)-39.73as on Dec 31, 2025
- EBITDA-$978.33 M (USD)-26.14as on Dec 31, 2025
- Latest Funding Round$450M (USD), Post-IPO
Jan 2018
- Investors
- Employee Count1,270
- Investments & AcquisitionsAdrestia
& 1 more
Products & Services of Insmed
Insmed offers a comprehensive portfolio of products and services, including ARIKAYCE, Brensocatib, and TPIP.
Treatment for nontuberculous mycobacterial lung disease via inhalation.
Inhibitor targeting inflammatory diseases in clinical development.
Early-stage compound for potential disease therapies.
Apps and channels of Insmed
its YouTube channel Insmed has 101 subscribers and 30 videos.
Videos from Insmed
The most watched videos on Insmed's YouTube channel, Insmed (101 subscribers). Click a video to play it here.
More on Insmed.
Funding Insights of Insmed
- Total Rounds 2
- Last Round Post-IPO — $450M
- First Round $489,000
(Dec 2010)
- Investors Count 1
All 2 funding rounds of Insmed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $450M | Post-IPO | – | – | – |
| Dec 2010 | $489,000 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Insmed
Insmed has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include United States Department of Agriculture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Leadership is provided on agriculture, food, and rural development matters. | 1862 | usda.gov | - |
Investor details for Insmed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Insmed
468 people are tracked at Insmed (291 in leadership, 8 in board & advisors, 169 in team); the tracked headcount is 1,270.
| Name | Role | Group |
|---|---|---|
Will Lewis | CEO | Leadership |
Sasha Rose | Senior Director, Biologics Research | Leadership |
Roger Adsett | Chief Operating Officer | Leadership |
Maria Jackson | Sr. Key Account Director | Leadership |
William H. Lewis | CEO & Chairman | Leadership |
Tricia Bajaj | Associate Director Of Equity Compensation | Leadership |
Larisa Ruiz Serrano | Associate Director, Medical Science Liaison | Leadership |
Matthew Levy | Executive Director, Talent Acquisition | Leadership |
Guillaume Floc'H | Director, IT Clinical & Commercial-enterprise EU | Leadership |
Bart Gradek (Bartosz) | Associate Director, IT Change Management | Leadership |
William Eyer | Associate Director, IT Infrastructure And Security | Leadership |
Monika Ciesielska | Senior Director Biostatistics | Leadership |
Sean E. | Director Lab And Research Technology | Leadership |
Jamie Gordon | Regional Sales Director | Leadership |
Andrew Thach | Director, Health Economics And Outcomes Research | Leadership |
Michelle Carangelo | Director Global Medical Training | Leadership |
Zhiying Qiu | Director Biostatistics | Leadership |
Martina Flammer | Chief Medical Officer | Leadership |
Shanna Price | Regional Director, US Field Medical | Leadership |
Sebastián Fucile M.D., Msc | Sr. Medical Director - Global Medical Affairs | Leadership |
448 more people are available in the full profile.
Complete people profiles for Insmed
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Insmed
Insmed is a publicly listed company on the NASDAQ with ticker symbol INSM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jun 2000
- Listed onNASDAQ: INSM
- Listed entityInsmed Incorporated
- Exchange sectorHealth technology
- ISINUS4576693075
- Share price$100.48 (-1.24% on the day) · 2026-10-08
- Market capitalisation$21.94B
- EPS (diluted, trailing year)$-4.11
- Volume (last session)5,251,782
Financials of Insmed
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $606.4M | -$1.28B | -$978.3M |
| 2024 | $363.7M | -$913.8M | -$775.6M |
| 2023 | $305.2M | -$749.6M | -$670.4M |
| 2022 | $245.4M | -$481.5M | -$453.9M |
| 2021 | $188.5M | -$434.6M | -$339.3M |
Detailed financial statements for Insmed
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Insmed
Insmed has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adrestia and Transave.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical drugs for multiple therapeutic areas are manufactured. | adrestia.com | Babraham, United Kingdom | 2018 | Jul 2023 | •••• | |
Developer of inhaled pharmaceuticals for the site-specific treatment of serious lung infections | transaveinc.com | Monmouth Junction, United States | 1997 | Dec 2010 | •••• |
Complete acquisition details for Insmed
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Insmed
6 dated milestones of Insmed across 24 years, from founding to its latest funding, stage changes and deals.
Competitors of Insmed
Insmed operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Affinivax, Eligo Bioscience, Aridis Pharma, Basilea and MaaT Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases | |
| basilea.com | 1999 | Basel, Switzerland | – | – | Antibiotics, antifungals, and oncology drugs are developed for disease treatment. | |
| maatpharma.com | 2014 | Lyon, France | $42.3M | – | Microbiome therapies are developed for treating intestinal dysbiosis diseases. | |
| eubiologics.com | 2012 | Seoul, South Korea | $7.5M | – | Company providing customized services for development and manufacturing biologics from both mammalian cell and microbial-based systems. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI | |
| gedeabiotech.com | 2015 | Lund, Sweden | $1.63M | – | Provider of therapeutics for treating vaginal microbial infections |
Detailed competitors of Insmed
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Insmed
The website of Insmed (insmed.com) receives about 68.8K visits a month and ranks #433,178 among all websites worldwide, #392 in Biotechnology and Pharmaceuticals.
- Monthly visits68.8K
▼ 14.8% vs previous month
- Unique visitors39.6K
per month
- Global rank#433,178
among all websites
- Category rank#392
Health · Biotechnology and Pharmaceuticals
- Bounce rate66%
- Pages per visit2.3
- Average visit1 min 44 sec
- DevicesDesktop 68% · Mobile 32%
Websites whose visitors overlap most with Insmed. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
crimsonpharma.com | crimsonpharma.com | 100% | – | – | – |
| biopharma.com | 100% | 1.7K | #9,262,866 | View details | |
| jerini.com | 100% | – | – | View details | |
scottish-biomedical.com | scottish-biomedical.com | 100% | – | – | – |
| cambrex.com | 100% | 35K | #883,665 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 23 similar websites and full traffic analytics for Insmed
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 23 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Insmed
Complete news archive for Insmed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Insmed
10 companies that operate in the same segment as Insmed (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Insmed
Insmed was founded in 1999 and raised its 1st funding round 11 years after it was founded.
Insmed is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
Will Lewis is the current CEO of Insmed.
Insmed has 1,270 employees.
Annual revenue of Insmed is $606.42M as on Dec 31, 2025.
Developer of small molecule inhibitors for rare lung diseases. Its lead candidate is Arikayce (liposomal amikacin for inhalation), a ribosomal 30S subunit inhibitor for nontuberculous mycobacteria (NTM) lung disease. It also has an earlier-stage clinical pipeline which includes INS1009, a nebulized prodrug formulation of treprostinil that claims to have potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) sarcoidosis, and severe refractory asthma.
Insmed's top competitors include Aridis Pharma, MaaT Pharma and Basilea.
Insmed offers ARIKAYCE, Brensocatib, and TPIP.
Yes, Insmed is publicly traded on NASDAQ under the ticker symbol INSM.
Insmed has 1 investor. Key investors include United States Department of Agriculture.
Insmed operates through Insmed Incorporated.